CXCL10 and dermatomyositis: Recently, in a cross‐sectional cohort of patients with juvenile DM, we demonstrated that 3 proteins, galectin‐9, CXCL10, and tumor necrosis factor receptor type II, can distinguish between juvenile DM patients with active disease and those in remission, with galectin‐9 and CXCL10 being the most discriminative markers 26, 27.